Widespread renal polycystosis induced by crizotinib

Marco Di Girolamo, Ida Paris, Francesco Carbonetti, Elisa Concetta Onesti, Fabio Socciarelli, Paolo Marchetti

Research output: Contribution to journalArticlepeer-review


With the widespread availability of biological antitumor drugs, the current scene of chemotherapies is changing. New chemotherapy agents, such as crizotinib, an inhibitor of anaplastic lymphoma kinase (ALK) and ROS1, usually used in pretreated advanced ALK-positive non-small-cell lung carcinoma, are more often used, and a description of the onset of side effects with suggestions for their management could be of interest for physicians. We describe a case of diffuse and aggressive renal polycystosis induced by crizotinib, which regressed after therapy, which could be of interest considering its wide extension and disappearance after the end of treatment. We also suggest some considerations from the literature and from the case reported that could be helpful in the management of this condition, which is known to be caused by crizotinib treatment.

Original languageEnglish
Pages (from-to)e128-e131
Issue number4
Publication statusPublished - Jul 1 2015


  • Adverse reactions
  • Drug-related side effects
  • Kidney diseases
  • Lung neoplasms
  • Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)


Dive into the research topics of 'Widespread renal polycystosis induced by crizotinib'. Together they form a unique fingerprint.

Cite this